Discover investment opportunities in Biotech Stocks 2024 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Biotech Stocks 2024 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Biotech Stocks 2024 using our Smart AI Filter.
9 stocks found for "Biotech Stocks 2024"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.22 | ±27.3% | 15.0 | 2.83% | |||
0.36 | ±26.9% | 24.5 | 0.00% | |||
1.09 | ±40.2% | -7.8 | 0.00% | |||
0.60 | ±39.2% | 20.8 | 0.00% | |||
1.34 | ±55.5% | -10.4 | 0.00% | |||
0.30 | ±26.0% | 12.1 | 0.66% | |||
0.34 | ±25.2% | 8.0 | 0.00% | |||
0.83 | ±70.5% | -3.5 | 0.00% | |||
0.63 | ±35.0% | 27.1 | 0.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: What factors could affect the performance of biotech stocks like VRTX and REGN in 2024?
A: Biotech stocks such as VRTX and REGN may be influenced by clinical trial results, FDA approvals, and patent expirations in 2024. The regulatory environment and advances in precision medicine may also impact their performance. Diversification within drug pipelines can potentially offset specific risks.
Q: How do the revenue streams of GILD and AMGN compare within the biotech sector?
A: GILD primarily generates revenue from its treatments for HIV and liver diseases like hepatitis, while AMGN has a diversified product line, including oncology and cardiovascular therapies. Both companies benefit from strong franchise medicines but face competition from biosimilars.
Q: Are dividend yields from AMGN and GILD appealing for income-focused investors?
A: AMGN and GILD both offer dividends, which may appeal to income-focused investors. However, biotech dividends can be influenced by reinvestment needs in research and development, so investors should evaluate sustainability and growth potential.
Q: How can regulatory changes impact the growth prospects of CRSP and MRNA?
A: CRSP and MRNA, involved in cutting-edge genomic editing and mRNA technologies, respectively, could be significantly impacted by regulatory changes. Stringent regulations may slow product approvals, while supportive policies could enhance growth prospects.
Q: What potential does SGEN have in the oncology sector?
A: SGEN specializes in antibody-drug conjugates for cancer treatment, offering significant potential in oncology due to its innovative pipeline. Success depends on FDA approvals and competition from alternative treatments, as well as collaboration with larger pharmaceutical firms.
Q: How vulnerable are biotech stocks like INCY and BIIB to broader economic cycles?
A: Biotech stocks like INCY and BIIB may exhibit less sensitivity to economic cycles compared to consumer goods, as demand for innovative treatments can remain steady. However, funding availability and investor sentiment could influence stock volatility.
Investors with an interest in Medical - Drugs stocks have likely encountered both Grifols (GRFS) and Neurocrine Biosciences (NBIX). But which of these two stocks offers value investors a better bang for their buck right now?
Read morePresident Donald Trump demanded several pharmaceutical companies cut down their drug prices for American consumers Thursday, issuing a Sept. 29 deadline for the businesses to 'end the free ride of American innovation by European and other developed nations."
Read more